Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005
- PMID: 18419393
- DOI: 10.1086/522161
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005
Erratum in
- J Infect Dis. 2014 Dec 15;210(12):2021
Abstract
Widespread use of varicella vaccine in the United States could enable detection of rare adverse events not identified previously. We reviewed data from 1995 to 2005 from the Vaccine Adverse Event Reporting System, including data from laboratory analyses, to distinguish adverse events associated with wild-type varicella-zoster virus (VZV) versus those associated with vaccine strain. Almost 48 million doses of varicella vaccine were distributed between 1995 and 2005. There were 25,306 adverse events reported (52.7/100,000 doses distributed); 5.0% were classified as serious (2.6/100,000 doses distributed). Adverse events associated with evidence of vaccine-strain VZV included meningitis in patients with concurrent herpes zoster. Patients with genetic predispositions may rarely have disease triggered by receipt of varicella vaccine. Overall, serious adverse events reported after varicella vaccination continue to be rare and must be considered relative to the substantial benefits of varicella vaccination. Ongoing safety surveillance and further studies may shed light on some of the hypothesized associations.
Similar articles
-
Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.Hum Vaccin Immunother. 2018;14(8):1963-1969. doi: 10.1080/21645515.2018.1456598. Epub 2018 May 18. Hum Vaccin Immunother. 2018. PMID: 29580194 Free PMC article.
-
Varicella Virus Vaccination in the United States.Viral Immunol. 2018 Mar;31(2):96-103. doi: 10.1089/vim.2017.0136. Epub 2017 Nov 27. Viral Immunol. 2018. PMID: 29173081 Free PMC article. Review.
-
Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).Vaccine. 2010 Aug 16;28(36):5878-82. doi: 10.1016/j.vaccine.2010.06.056. Epub 2010 Jun 30. Vaccine. 2010. PMID: 20600487
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
-
Postlicensure safety surveillance for varicella vaccine.JAMA. 2000 Sep 13;284(10):1271-9. doi: 10.1001/jama.284.10.1271. JAMA. 2000. PMID: 10979114
Cited by
-
The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.Int J Mol Sci. 2023 Nov 9;24(22):16112. doi: 10.3390/ijms242216112. Int J Mol Sci. 2023. PMID: 38003300 Free PMC article. Review.
-
Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study.Vaccines (Basel). 2023 Aug 24;11(9):1416. doi: 10.3390/vaccines11091416. Vaccines (Basel). 2023. PMID: 37766093 Free PMC article.
-
Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.Lancet Reg Health West Pac. 2023 Feb 18;34:100707. doi: 10.1016/j.lanwpc.2023.100707. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283962 Free PMC article.
-
Meningitis without Rash after Reactivation of Varicella Vaccine Strain in a 12-Year-Old Immunocompetent Boy.Vaccines (Basel). 2023 Jan 30;11(2):309. doi: 10.3390/vaccines11020309. Vaccines (Basel). 2023. PMID: 36851187 Free PMC article.
-
Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005-2021.Vaccines (Basel). 2022 Dec 16;10(12):2165. doi: 10.3390/vaccines10122165. Vaccines (Basel). 2022. PMID: 36560575 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
